Clinical Trials Browser

Active not recruiting × Carcinoma, Hepatocellular × lenvatinib × Clear all

NCT05301842 2026-04-07

EMERALD-3

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 2 FDA

Gastrointestinal

Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05113186 2026-01-29

LENVABLA

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05822752 2025-08-14

LIVIGNO-1

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06138769 2024-07-03

Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular